Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH

Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH

ash

3 months
20 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Chronic Lymphocytic Leukemia
Description:

John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL).

Up Next Autoplay
Servier's R&D Efforts in Oncology #ASH #ASH19
Servier's R&D Efforts in Oncology #ASH #ASH19
Free
183
ash 2 months
Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant #ASH19 @ClevelandClinic
Post-Transplant Work Status of Young Adult Survivors of Allogeneic Hematopoietic Cell Transplant #ASH19 @ClevelandClinic
Free
27
ash 3 months
Are Racial Disparities in AML Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
Are Racial Disparities in AML Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?
Free
24
ash 3 months
Multiple Myeloma Disparities #ASH19 @WinshipAtEmory
Multiple Myeloma Disparities #ASH19 @WinshipAtEmory
Free
41
ash 3 months
Phase III Lumoxiti #ASH19
Phase III Lumoxiti #ASH19
Free
51
ash 3 months
Comparative Outcomes of Relapsed Follicular Lymphoma Patients #ASH19 @ClevelandClinic
Comparative Outcomes of Relapsed Follicular Lymphoma Patients #ASH19 @ClevelandClinic
Free
43
ash 3 months
Sickle Cell Research #ASH19
Sickle Cell Research #ASH19
Free
8
ash 3 months
CASIRE Study #ASH19
CASIRE Study #ASH19
Free
19
ash 3 months
GRIFFIN Study Update #ASH19 @LevineCancer
GRIFFIN Study Update #ASH19 @LevineCancer
Free
12
ash 3 months
Analysis of Brentuximab Vedotin Plus CHP (A+CHP) #ASH19 @OfficialUoM
Analysis of Brentuximab Vedotin Plus CHP (A+CHP) #ASH19 @OfficialUoM
Free
14
ash 3 months